Global TradFi & Macroeconomics

Focus on price action and volatility across stocks, bonds, forex, commodities, and major indices. Analyze macro indicators like interest rates, inflation, employment, and policy expectations to decode global liquidity shifts, risk sentiment, and cross-market correlations.
All
Stocks
Metals
Indices
Forex
Commodities

Chinese Economists Forecast August CPI Growth at 0.7%-0.9%, PPI to Ease

According to economists from China's Institute for New Economy Research and Caitong Securities, August consumer price inflation (CPI) is expected to grow modestly at 0.7% to 0.9% year-over-year. Zhu Keli, founder of the Institute for New Economy Research, forecasts August CPI growth at 0.7%, while S
GateNews·09-02 23:03
Chinese Economists Forecast August CPI Growth at 0.7%-0.9%, PPI to Ease

Humax Holdings Merges with Humax to Avoid KOSDAQ Delisting

Humax Holdings approved a merger with its subsidiary Humax on August 28 at an extraordinary shareholders meeting, with the merger taking effect October 1. The decision came after Humax Holdings' market capitalization remained below the 20 billion won threshold starting March 6, triggering
LucasBennett·09-02 22:57
Humax Holdings Merges with Humax to Avoid KOSDAQ Delisting

Trump Says Stock Market Will Continue to Rise, September 3

According to BlockBeats, President Trump said on September 3 that the U.S. stock market has not been affected and will continue to rise. Speaking at the White House, Trump stated that the market could potentially be higher than current
GateNews·09-02 22:53
Trump Says Stock Market Will Continue to Rise, September 3

RARE Stock Drops 46% After Angelman Syndrome Drug Trial Fails

Ultragenyx Pharmaceutical (RARE) stock plunged 46% in after-hours trading Wednesday after the company announced its experimental Angelman syndrome drug apazunersen failed a late-stage clinical trial. The stock closed regular trading at $26.53 before sliding into the mid-teens after hours. The late-s
LucasBennett·09-02 22:50
RARE Stock Drops 46% After Angelman Syndrome Drug Trial Fails